Novavax has purchased Praha Vaccines, a biologics manufacturer in the Czech Republic, to support mass production of its COVID-19 vaccine.
AB201, a potential protein-based treatment for blood clotting related to COVID-19, will be developed by ARCA Biopharma towards the clinic.
Wisconsin-based Waisman Biomanufacturing will produce the vaccine under development by Heat Biologics for the virus that causes COVID-19.
The NDA submission is intended to support the approval of Tivozanib as a treatment for adult renal cell carcinoma in the United States.
Tecentriq (atezolizumab) has been approved by the FDA as a first-line treatment for adult PD-L1-high metastatic non-small cell lung cancer.
Patient enrollment in the phase 1/2 trial of NVX-CoV2373 has already started with preliminary phase 1 trial data expected in July of 2020.
Dupixent (dupilumab), developed by Regeneron and Sanofi, has shown “significant efficacy” for Eosinophilic Esophagitis in a phase 3 trial.
Potential NantKWest COVID-19 therapy BM-AlloMSC will be tested in a phase 1b clinical trial with cell product from Be The Match BioTherapies.